China These authors contributed equally to this work. Correspondence to: Dr. Xi Cao, Beijing Diabetes Institute, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Eric Green; Chairman of the Board, President, Chief Executive Officer; West Pharmaceutical Services Inc Bernard Birkett; Chief Financial and Operations Officer, Senior Vice President; West ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Popular drugs for weight loss are being prescribed to kids as young as 12. [DOWNLOAD: Free WSB-TV News app for alerts as news ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

Both GLP-1 RAs and SGLT2is are associated with a reduced risk for Alzheimer disease and related dementias among people with type 2 diabetes.

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.

As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most ...